In-vivo data to the highest technical and scientific standards
Scantox is the leading Nordic preclinical GLP accredited CRO – Contract Research Organization.
Based on decades of experience we are a trusted partner for in-vivo preclinical research services for the pharmaceutical and medical device industries. The Scantox services enable clients to progress their drug or device development based on consistent, high-quality solid data to the highest technical and scientific standards.
Scantox Services
Our main focus is on pharmacology and regulatory toxicology and based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries.
Our services span from handling and formulating test items over in-life studies to histopathology producing tissue slides for reviewing by our experienced team of pathologists.
Furthermore, we offer all standard clinical pathology analysis as well as specialized biomarkers that are required according to international toxicology guidelines. Dose formulation analysis, bioanalysis as well as safety pharmacology testing are also part of our core capabilities.
Upcoming Events
Blog & News
Key Steps to Get Your IND Schedule on Track
Preparing for an Investigational New Drug (IND) application represents a key milestone for First-In-Human (FIH) studies. For many drug developers, especially those newer to the field, navigating this process can be complex. To simplify this journey, we dive into the...
Scantox closes the acquisition of QPS Neuropharmacology – now Scantox Neuro
2 April 2024 -- Today Scantox, together with its majority owner Impilo, finalized the acquisition of QPS Neuropharmacology, a leading drug discovery CRO specialized in neurodegenerative, rare diseases and mental disorders. The company, as of today integrated into the...
Visit Scantox at SOT in Salt Lake City: Discover Expanded Service Offerings and Collaborative Atmosphere
As the Society of Toxicology (SOT) Annual Meeting approaches, biopharmaceutical companies have a prime opportunity to engage with industry leaders and explore innovative solutions to advance drug development initiatives. This year, the team at Scantox extends a warm...
Careers
Join our team of professionals
We are continuously looking for new talents to join our team. Check out our open positions or send us an unsolicited application.
Scientific Excellence
With over 20 years of extensive experience, we are considered global leaders within minipig toxicology studies, with studies conducted in Göttingen Minipigs.
We work to the highest scientific standards, and engage with partners in scientific collaborations to provide the best scientific results and highest degree of knowledge.
Scantox is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a world leader in scientific research based on Göttingen Minipigs.
The Scantox Name
The Scantox name dates back to 1977. It holds the story of our geographic origination – SCANdinavia – and of our original key area of expertise – TOXicology.
Today Scantox is an international corporation, and our areas of expertise have expanded into a vast portfolio of preclinical study types. But our roots and values remain.
We are Scantox.
Our Mission
The Scantox team is passionate about our common mission to improve the health of people, by creating life-changing scientific results. Every day.
Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo.
Scantox locations
Scantox is headquartered in Denmark with a number of international subsidiaries enabling us to provide a wide range of CRO services in the various stages of the drug development process.
Contact us for further information:
+45 5686 1500Contact us for further information: +45 5686 1500
About Scantox Group
Scantox is the leading Nordic preclinical GLP-accredited Contract Research Organization, focused on pharmacology and regulatory toxicology. We are headquartered in Denmark, in the same location as where the company was originally founded in 1977. In addition Scantox has subsidiaries in Sweden and Austria.
Scantox is specialized in preclinical contract research services. Our scientific work enables pharmaceutical and biotechnology companies to progress drug development projects, based on solid high-quality data. Core competencies within the Scantox Group include Explorative and efficacy studies, PK-studies, general toxicology studies including Juvenile & EFD, local tolerance studies, wound healing studies and vaccines. GLP and GMP compliant. Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into studies in early discovery as well as preclinical tests that overlap into phases 1 and 2.
As one of the most experienced preclinical service providers, our in-vivo work is backed by decades of experience. This makes Scantox a highly trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a globally recognized leader for our expertise and long experience with the Göttingen Minipig. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Scantox is today owned by Impilo, the leading Nordic healthcare investment company.